Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Earl Wilson

Neurology Bristol, TN Medical Doctor

NPI 1568455244 CMS profile 298082

3183 W State St, Suite 1201, Bristol, TN 37620

Open in the dashboard

General payments

$16,601

860 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Earl Wilson of Bristol, TN is reported in the CMS Open Payments database as having received $16,601 across 860 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,576 113
2024 General $2,835 138
2023 General $2,545 124
2022 General $2,447 125
2021 General $1,962 114
2020 General $1,471 83
2019 General $2,765 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Earl Wilson
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Earl Wilson were reported at $2,576. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Earl Wilson Neurology median Middle half National median
2019 $2,765 $474 $118–$2,177 $163
2020 $1,471 $367 $82–$2,309 $114
2021 $1,962 $438 $104–$2,547 $132
2022 $2,447 $442 $103–$2,388 $149
2023 $2,545 $464 $119–$2,312 $160
2024 $2,835 $468 $119–$2,323 $164
2025 $2,576 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $2,039 74 payments
  2. AbbVie, Inc. $1,288 103 payments
  3. Alexion Pharmaceuticals, Inc. $1,167 51 payments
  4. Novartis Pharmaceuticals Corporation $915 49 payments
  5. Lilly USA, LLC $809 45 payments
  6. Neurelis, Inc. $665 21 payments
  7. US WorldMeds, LLC $641 34 payments
  8. Biogen, Inc. $635 36 payments
  9. Lundbeck LLC $533 28 payments
  10. Teva Pharmaceuticals USA, Inc. $490 28 payments
  11. Other $7,420 391 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,457 855 payments
  2. Education $122 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23 1 payment
Products named General payments · program years 2019–2025
  1. Briviact $1,225 48 payments
  2. UBRELVY $824 72 payments
  3. QULIPTA $699 62 payments
  4. VALTOCO $665 21 payments
  5. ULTOMIRIS $649 27 payments
  6. AIMOVIG $452 23 payments
  7. NURTEC ODT $421 24 payments
  8. Nayzilam $417 10 payments
  9. ZEPOSIA $416 23 payments
  10. EMGALITY $414 26 payments
  11. Other $12,082 650 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

1,975

Median for Neurology: 833

Drug cost

$482,364

Median for Neurology: $202,670

Branded share of claims

32.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 33 $175,028
Botox Onabotulinumtoxina Brand 42 $64,111
Nurtec Odt Rimegepant Sulfate Brand 33 $36,250
Ubrelvy Ubrogepant Brand 28 $32,062
Emgality Pen Galcanezumab-Gnlm Brand 31 $29,368
Aimovig Autoinjector Erenumab-Aooe Brand 28 $21,235
Briviact Brivaracetam Brand 15 $20,309
Rexulti Brexpiprazole Brand 11 $18,772
Glatiramer Acetate Generic 13 $18,002
Lacosamide Generic 86 $11,468

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$37,194

Medicare's payments for the services billed

Medicare patients

278

Average age 74

Services billed

513

147 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 40%
Diabetes 36%
Depression 36%
Chronic kidney disease 35%
Atrial fibrillation 23%
Alzheimer's or dementia 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Nayzilam
$309 — —
Briviact
$286 15 —
ULTOMIRIS
$227 — —
VYEPTI
$155 — —
Apokyn
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

860 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record